J&J Continues Atopic Dermatitis Effort With Numab Deal

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Johnson & Johnson, after several prior failed R&D attempts in AD, will pay Numab $1.25bn to acquire a subsidiary and its Phase II-ready bispecific antibody for key unmet needs in the disease.

Hockey net (shots on goal)
Johnson & Johnson is lining up multiple shots at treating atopic dermatitis • Source: Shutterstock

Johnson & Johnson unveiled its second atopic dermatitis-focused deal this month on 28 May, paying $1.25bn in cash to acquire a subsidiary of Numab Therapeutics AG that houses a Phase II-ready bispecific antibody that J&J thinks will offer a novel approach to addressing two distinct disease-driving pathways in AD.

Key Takeaways

  • Johnson & Johnson is paying $1.25bn for Numab’s IL-4Rα and IL-31-targeted bispecific for development in atopic dermatitis.

The agreement follows J&J’s 16 May deal to acquire privately held Proteologix for $850m, driven by preclinical PTX128, an antibody...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.